Evidence map›Paper›PMID 33026561›Full record

ArticleEJNMMI research2020

Quantitative evaluation of hepatic integrin α

Shuichi Hiroyama, Takemi Rokugawa, Miwa Ito, Hitoshi Iimori, Ippei Morita, Hiroki Maeda, Kae Fujisawa, Keiko Matsunaga, Eku Shimosegawa, Kohji Abe

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Evaluation of an Integrin αNuclear medicine and molecular imaging · 2023
    Article
  6. Article
  7. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shuichi HiroyamaTranslational Research Unit, Biomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan. shuichi.hiroyama@shionogi.co.jp.
Takemi RokugawaTranslational Research Unit, Biomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Miwa ItoTranslational Research Unit, Biomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Hitoshi IimoriResearch Laboratory for Development, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Ippei MoritaLaboratory for Advanced Medicine Research, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Hiroki MaedaLaboratory for Innovative Therapy Research, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Kae FujisawaResearch Laboratory for Development, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Keiko MatsunagaDepartment of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Eku ShimosegawaDepartment of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Kohji AbeTranslational Research Unit, Biomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka, 561-0825, Japan.
Futaba (Japan) · JPShionogi (Japan) · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntegrin α

methods

resultsBiochemical and histological evaluation confirmed the development of NASH rats. Integrin α

conclusionsWe have demonstrated that the V

Indexed as

Arginine–glycine–aspartic acid (RGD)FibrosisIntegrinNon-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)Positron emission tomography (PET)

Identifiers

PMID33026561
PMCPMC7541810
OpenAlexW3091780362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.